Navigation Links
S1P1 Lead Compounds, AMG 369 and AMG 277, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
Date:10/12/2011

WELLESLEY HILLS, Mass., Oct. 12, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 lead compounds, AMG 369 and AMG 277, will be offered December 8, 2011 in a sealed bid sale.

Some companies with S1P modulators in development currently are:  Novartis, Actelion, Lexicon, Pfizer, Ono Pharmaceuticals, Glaxo Smith Kline, Mitsubishi Tanabe Pharma, Receptos, Arena Pharmaceuticals, Exelixis, Boehringer Ingelheim, Biogen Idec, Kyorin, Angio, Apogee Biotechnology and Lpath.

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office – jffinnjr@finnwarnkegayton.com or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  He has been involved in loan workouts and bankruptcy cases for 37 years.  His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@finnwarnkegayton.com


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
2. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
3. U.S. Appeals Court Reinstates Claim That Controversial Diet Drug Redux Should Never Have Been Offered to American People
4. Free Prostate Screenings Offered at Virginia G. Piper Cancer Center
5. Humana and Walmart Announce Innovative Medicare Part D Prescription Drug Plan with Lowest National Monthly Premium Offered in all 50 States and D.C. (1)
6. Newly Revised Concepts in Clinical Pharmacokinetics Web-Based Continuing Education Course Offered by the University of Georgia
7. Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011
8. Exclusive Coverage for Kidney Dialysis Centers Offered by Five Star Healthcare
9. For Second Straight Year, Humana Walmart-Preferred Rx Plan (PDP) Features Lowest Monthly Premium Offered In All 50 States and Washington D.C.
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Mass. , March 23, 2017 Merrimack ... enrollment of its first patient in a Phase 1 ... antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and ... is overexpressed in 50-100% of many major tumor types, ... "The initiation of this study is an ...
(Date:3/23/2017)... , March 23, 2017 Global Colposcope Market ... on the Colposcope in Global market, especially in North ... Asia-Pacific , South America , ... report categorizes the market based on manufacturers, regions, type and application. ... Browse 190 Tables ...
(Date:3/23/2017)... 23, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... that the English version of the Annual report for 2016 ... ... NeuroVive NeuroVive Pharmaceutical AB is a leader in ... development of medicines that preserve mitochondrial integrity and function in ...
Breaking Medicine Technology:
(Date:3/23/2017)... Rey, CA (PRWEB) , ... March 23, 2017 ... ... its customizable coding audit software solution, iCode Assurance, at HCCA’s 21st annual Compliance ... optimizes and accelerates the coding audit process for all medical chart types with ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “Wounded Woman ... “Wounded Woman Be Ye Healed-Passing On A Legacy” is the creation of published author, ... founder of Comfortbearers grief ministry. She has been happily married to her husband, ...
(Date:3/23/2017)... ... 2017 , ... “A Respectful Response To Atheist Manifesto”: theological ... Manifesto” is the creation of published author Richard Hostetter, a former missionary in ... holds graduate degrees from Kent State University and the University of Ghana. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... the publication of “Profiling protein expression in circulating tumor cells using microfluidic western ... the use of the Vortex technology to capture CTCs and a ...
(Date:3/22/2017)... (PRWEB) , ... March 23, 2017 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... BioPharma Asia Convention, currently taking place at the Suntec Singapore International Exhibition & ...
Breaking Medicine News(10 mins):